A molecular revolution in uveal melanoma: Implications for patient care and targeted therapy

Ophthalmology

Volumn 121, Issue 6, 2014, Pages 1281-1288

  William Harbour, J ^a   Chao, Daniel L ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; CABOZANTINIB; EVEROLIMUS; ROMIDEPSIN; SELUMETINIB; SORAFENIB; SOTRASTAURIN; SUNITINIB; VORINOSTAT;

ARTICLE; FAMILIAL CANCER; GENE EXPRESSION PROFILING; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; TREATMENT PLANNING; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT CARE; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS;

EID: 84901776801     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.12.014     Document Type: Article

References (46)

1. J.W. Harbour The genetics of uveal melanoma: an emerging framework for targeted therapy Pigment Cell Melanoma Res 25 2012 171 181
2. A.D. Singh, and A. Topham Survival rates with uveal melanoma in the United States: 1973-1997 Ophthalmology 110 2003 962 965 (Pubitemid 36560497)
3. M.D. Onken, L.A. Worley, J.P. Ehlers, and J.W. Harbour Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death Cancer Res 64 2004 7205 7209 (Pubitemid 39372052)
4. F. Tschentscher, J. Husing, and T. Holter et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities Cancer Res 63 2003 2578 2584 (Pubitemid 36608917)
5. M.D. Onken, J.P. Ehlers, and L.A. Worley et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas Cancer Res 66 2006 4602 4609
6. S.H. Chang, L.A. Worley, M.D. Onken, and J.W. Harbour Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis Melanoma Res 18 2008 191 200 (Pubitemid 351684664)
7. M.D. Onken, A.Y. Lin, and L.A. Worley et al. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas Am J Ophthalmol 140 2005 748 749 (Pubitemid 41455330)
8. L.A. Worley, M.D. Onken, and E. Person et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma Clin Cancer Res 13 2007 1466 1471 (Pubitemid 46450436)
9. U. Petrausch, P. Martus, and H. Tonnies et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases Eye (Lond) 22 2007 997 1007
10. W. van Gils, E.M. Lodder, and H.W. Mensink et al. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis Invest Ophthalmol Vis Sci 49 2008 4254 4262
11. J.W. Harbour A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile M. Thurin, F.M. Marincola, Molecular Diagnostics for Melanoma: Methods and Protocols 2014 Springer New York 427 440 Methods in Molecular Biology. vol. 1102
12. M.D. Onken, L.A. Worley, and D.H. Char et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma Ophthalmology 119 2012 1596 1603
13. W. Maat, E.S. Jordanova, and S.L. van Zelderen-Bhola et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies Arch Pathol Lab Med 131 2007 91 96 (Pubitemid 46174141)
14. B. Damato, J.A. Dopierala, and S.E. Coupland Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification Clin Cancer Res 16 2010 6083 6092
15. Harbour JW, Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr [serial online] 2013;5. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/23591547. Accessed November 30, 2013.
16. J.W. Harbour Genomic, prognostic, and cell-signaling advances in uveal melanoma Am Soc Clin Oncol Educ Book 2013 388 391
17. M.D. Onken, L.A. Worley, and M.D. Long et al. Oncogenic mutations in GNAQ occur early in uveal melanoma Invest Ophthalmol Vis Sci 49 2008 5230 5234
18. C.D. Van Raamsdonk, V. Bezrookove, and G. Green et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi Nature 457 2009 599 602
19. C.D. Van Raamsdonk, K.G. Griewank, and M.B. Crosby et al. Mutations in GNA11 in uveal melanoma N Engl J Med 363 2010 2191 2199
20. J.W. Harbour, M.D. Onken, and E.D. Roberson et al. Frequent mutation of BAP1 in metastasizing uveal melanomas Science 330 2010 1410 1413
21. M. Carbone, L.K. Ferris, and F. Baumann et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs J Transl Med [serial online] 10 2012 179
22. Z.M. Eletr, and K.D. Wilkinson An emerging model for BAP1's role in regulating cell cycle progression Cell Biochem Biophys 60 2011 3 11
23. J.C. Scheuermann, A.G. de Ayala Alonso, and K. Oktaba et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB Nature 465 2010 243 247
24. J.W. Harbour, E.D. Roberson, and H. Anbunathan et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma Nat Genet 45 2013 133 135
25. M. Martin, L. Masshofer, and P. Temming et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 Nat Genet 45 2013 933 936
26. M.D. Leiserson, D. Blokh, R. Sharan, and B.J. Raphael Simultaneous identification of multiple driver pathways in cancer PLoS Comput Biol 9 2013 e1003054
27. J.J. Augsburger, Z.M. Correa, and A.H. Shaikh Effectiveness of treatments for metastatic uveal melanoma Am J Ophthalmol 148 2009 119 127
28. K.T. Flaherty, I. Puzanov, and K.B. Kim et al. Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
29. A. Weber, U.R. Hengge, and D. Urbanik et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea Lab Invest 83 2003 1771 1776 (Pubitemid 38018540)
30. W. Zuidervaart, F. van Nieuwpoort, and M. Stark et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS Br J Cancer 92 2005 2032 2038 (Pubitemid 40897426)
31. E. von Euw, M. Atefi, and N. Attar et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines Mol Cancer [serial online] 11 2012 22
32. A. Mahipal, L. Tijani, and K. Chan et al. A pilot study of sunitinib malate in patients with metastatic uveal melanoma Melanoma Res 22 2012 440 446
33. Selumetinib shows promise in metastatic uveal melanoma Cancer Discov 3 7 2013 OF8
34. M. Patel, E. Smyth, and P.B. Chapman et al. Therapeutic implications of the emerging molecular biology of uveal melanoma Clin Cancer Res 17 2011 2087 2100
35. J.S. Khalili, X. Yu, and J. Wang et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner Clin Cancer Res 18 2012 4345 4355
36. O. Abdel-Wahab, M. Adli, and L.M. LaFave et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression Cancer Cell 22 2012 180 193
37. S. Landreville, O.A. Agapova, and K.A. Matatall et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma Clin Cancer Res 18 2012 408 416
38. K.A. Matatall, O.A. Agapova, and M.D. Onken et al. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma BMC Cancer [serial online] 13 2013 371 Available at: http://www.biomedcentral.com/1471-2407/13/371 Accessed November 30, 2013
39. C.R. Canning, and J. Hungerford Familial uveal melanoma Br J Ophthalmol 72 1988 241 243
40. S. Pena-Llopis, S. Vega-Rubin-de-Celis, and A. Liao et al. BAP1 loss defines a new class of renal cell carcinoma Nat Genet 44 2012 751 759
41. T. Wiesner, A.C. Obenauf, and R. Murali et al. Germline mutations in BAP1 predispose to melanocytic tumors Nat Genet 43 2011 1018 1021
42. J.R. Testa, M. Cheung, and J. Pei et al. Germline BAP1 mutations predispose to malignant mesothelioma Nat Genet 43 2011 1022 1025
43. M.H. Abdel-Rahman, R. Pilarski, and C.M. Cebulla et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers J Med Genet 48 2011 856 859
44. P.N. Dayani, J.E. Gould, and D.B. Brown et al. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization Arch Ophthalmol 127 2009 628 632
45. K.V. Sharma, J.E. Gould, and J.W. Harbour et al. Hepatic arterial chemoembolization for management of metastatic melanoma AJR Am J Roentgenol 190 2008 99 104
46. J.J. Luke, M.K. Callahan, and M.A. Postow et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience Cancer 119 2013 3687 3695